|
1
|
Tomihara H, Eguchi H, Yamada D, Gotoh K,
Kawamoto K, Wada H, Asaoka T, Noda T, Takeda Y, Tanemura M, et al:
Preoperative chemoradiotherapy does not compromise the feasibility
of adjuvant chemotherapy for patients with pancreatic ductal
adenocarcinoma. Surg Today. 47:218–226. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirayama K, Kono H, Nakata Y, Akazawa Y,
Wakana H, Fukushima H and Fujii H: Expression of podoplanin in
stromal fibroblasts plays a pivotal role in the prognosis of
patients with pancreatic cancer. Surg Today. 48:110–118. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamada D, Eguchi H, Asaoka T, Tomihara H,
Noda T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, et al:
The basal nutritional state of PDAC patients is the dominant factor
for completing adjuvant chemotherapy. Surg Today. Apr 18–2017.(Epub
ahead of print). View Article : Google Scholar
|
|
4
|
Sharp P and Srai SK: Molecular mechanisms
involved in intestinal iron absorption. World J Gastroenterol.
13:4716–4724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oates PS: The role of hepcidin and
ferroportin in iron absorption. Histol Histopathol. 22:791–804.
2007.PubMed/NCBI
|
|
6
|
Franchini M, Montagnana M and Lippi G:
Hepcidin and iron metabolism: From laboratory to clinical
implications. Clin Chim Acta. 411:1565–1569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dixon SJ and Stockwell BR: The role of
iron and reactive oxygen species in cell death. Nat Chem Biol.
10:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamada Y, Miyamoto T, Kashima H, Kobara H,
Asaka R, Ando H, Higuchi S, Ida K and Shiozawa T: Lipocalin 2
attenuates iron-related oxidative stress and prolongs the survival
of ovarian clear cell carcinoma cells by up-regulating the CD44
variant. Free Radic Res. 50:414–425. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toyokuni S: Role of iron in
carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci.
100:9–16. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kano Y, Konno M, Ohta K, Haraguchi N,
Nishikawa S, Kagawa Y, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T,
et al: Jumonji/Arid1b (Jarid1b) protein modulates human esophageal
cancer cell growth. Mol Clin Oncol. 1:753–757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohta K, Haraguchi N, Kano Y, Kagawa Y,
Konno M, Nishikawa S, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T, et
al: Depletion of JARID1B induces cellular senescence in human
colorectal cancer. Int J Oncol. 42:1212–1218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roesch A, Fukunaga-Kalabis M, Schmidt EC,
Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T
and Herlyn M: A temporarily distinct subpopulation of slow-cycling
melanoma cells is required for continuous tumor growth. Cell.
141:583–594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z,
Ma Y, Yu Y, Lin H, Chen AP and Chen CD: JARID1B is a histone H3
lysine 4 demethylase up-regulated in prostate cancer. Proc Natl
Acad Sci USA. 104:19226–19231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barrett A, Madsen B, Copier J, Lu PJ,
Cooper L, Scibetta AG, Burchell J and Taylor-Papadimitriou J: PLU-1
nuclear protein, which is upregulated in breast cancer, shows
restricted expression in normal human adult tissues: A new
cancer/testis antigen? Int J Cancer. 101:581–588. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weizer-Stern O, Adamsky K, Margalit O,
Ashur-Fabian O, Givol D, Amariglio N and Rechavi G: Hepcidin, a key
regulator of iron metabolism, is transcriptionally activated by
p53. Br J Haematol. 138:253–262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh B, Arora S, Agrawal P and Gupta SK:
Hepcidin: A novel peptide hormone regulating iron metabolism. Clin
Chim Acta. 412:823–830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao N, Zhang AS and Enns CA: Iron
regulation by hepcidin. J Clin Invest. 123:2337–2343. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bekri S, Gual P, Anty R, Luciani N, Dahman
M, Ramesh B, Iannelli A, Staccini-Myx A, Casanova D, Ben Amor I, et
al: Increased adipose tissue expression of hepcidin in severe
obesity is independent from diabetes and NASH. Gastroenterology.
131:788–796. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue D, Zhou CX, Shi YB, Lu H and He XZ:
Decreased expression of ferroportin in prostate cancer. Oncol Lett.
10:913–916. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li JJ, Meng X, Si HP, Zhang C, Lv HX, Zhao
YX, Yang JM, Dong M, Zhang K, Liu SX, et al: Hepcidin destabilizes
atherosclerotic plaque via overactivating macrophages after
erythrophagocytosis. Arterioscler Thromb Vasc Biol. 32:1158–1166.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang S, Chen Y, Guo W, Yuan L, Zhang D,
Xu Y, Nemeth E, Ganz T and Liu S: Disordered hepcidin-ferroportin
signaling promotes breast cancer growth. Cell Signal. 26:2539–2550.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Asukai K, Kawamoto K, Eguchi H, Konno M,
Nishida N, Koseki J, Noguchi K, Hasegawa S, Ogawa H, Yamada D, et
al: Prognostic impact of peritumoral IL-17-positive cells and IL-17
axis in patients with intrahepatic cholangiocarcinoma. Ann Surg
Oncol. 22 Suppl 3:S1524–S1531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kulaksiz H, Fein E, Redecker P, Stremmel
W, Adler G and Cetin Y: Pancreatic beta-cells express hepcidin, an
iron-uptake regulatory peptide. J Endocrinol. 197:241–249. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
D'Angelo G: Role of hepcidin in the
pathophysiology and diagnosis of anemia. Blood Res. 48:10–15. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pietrangelo A: Hereditary hemochromatosis:
Pathogenesis, diagnosis, and treatment. Gastroenterology.
139:393–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Domenico I, Ward DM and Kaplan J:
Hepcidin and ferroportin: The new players in iron metabolism. Semin
Liver Dis. 31:272–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ciniselli CM, De Bortoli M, Taverna E,
Varinelli L, Pizzamiglio S, Veneroni S, Bonini C, Orlandi R,
Verderio P and Bongarzone I: Plasma hepcidin in early-stage breast
cancer patients: No relationship with interleukin-6, erythropoietin
and erythroferrone. Expert Rev Proteomics. 12:695–701. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ward DG, Roberts K, Brookes MJ, Joy H,
Martin A, Ismail T, Spychal R, Iqbal T and Tselepis C: Increased
hepcidin expression in colorectal carcinogenesis. World J
Gastroenterol. 14:1339–1345. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Q, Wang L, Ma Y, Wu X, Jin L and Yu
F: Increased hepcidin expression in non-small cell lung cancer
tissue and serum is associated with clinical stage. Thorac Cancer.
5:14–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo W, Zhang S, Chen Y, Zhang D, Yuan L,
Cong H and Liu S: An important role of the hepcidin-ferroportin
signaling in affecting tumor growth and metastasis. Acta Biochim
Biophys Sin (Shanghai). 47:703–715. 2015. View Article : Google Scholar : PubMed/NCBI
|
